Re:Blood-thinning drug could transform stroke treatment

[Guest guest]

There have been over 600 studies proving fish oil is  just as effective as blood

thinning drug with out the negative side effects. The real issue isn't what is

best it is about pharmaceutical profit.

 

--- On Tue, 9/1/09, Jim Clark <huuman60 wrote:

 

 

Jim Clark <huuman60

<< >> Re:Blood-thinning drug could transform

stroke treatment

 

Tuesday, September 1, 2009, 12:12 PM

 

 

 

 

 

 

 

 

Then, of course, you could just change to a more healthy diet,

but that would be way too easy.

 

Posted by: " virgil " virgil (AT) hillbre (DOT) plus.com

<virgil (AT) hillbre (DOT) plus.com?Subject=%20Re% 3ABlood-thinning

%20drug%20could% 20transform% 20stroke% 20treatment>

bodelva7 <http://profiles. / bodelva7>

 

Mon Aug 31, 2009 7:38 pm (PDT)

 

http://www.independ ent.co.uk/ life-style/ health-and- families/ health-news/

bloodthinning- drug-could- transform- stroke-treatment -1779631. html

<http://www.independ ent.co.uk/ life-style/ health-and- families/ health-news/

bloodthinning- drug-could- transform- stroke-treatment -1779631. html>

 

By John von Radowitz

 

Monday, 31 August 2009

 

A new blood-thinning drug could end the use of rat poison as a primary

medical treatment to prevent stroke, it was claimed today.

 

For half a century, thousands of patients at risk of stroke have been

given warfarin to prevent blood clotting. But treatment with the drug,

commonly used to kill vermin, is risky.

 

Doses have to be carefully watched and adjusted to prevent excessive

bleeding from cuts or stomach ulcers, requiring frequent clinic visits.

Warfarin can also interact badly with other drugs and certain foods.

 

The new drug, Pradaxa, works in a different way and is far safer.

Patients taking the pill twice a day do not have to be constantly

checked for signs of overdosing, and can eat what they like.

 

Results from a major trial showed that Pradaxa was 34 per cent better at

reducing the risk of stroke and blood clots in at-risk patients than

well-controlled warfarin. More than 18,000 patients from 44 countries

took part in the three-year RE-LY (randomised evaluation of long term

anticoagulant therapy) trial, the largest of its kind ever conducted.

 

Participants had an average age of 71 and all suffered from atrial

fibrillation, a heart rhythm disorder that greatly increases the risk of

stroke. They were randomly assigned to treatment either with Pradaxa or

warfarin.

 

The findings were published online in the New England Journal of Medicine.

 

Professor Stuart Connolly, one of the leading investigators from

McMaster University in Hamilton, Canada, said: " We now have an oral

treatment which offers superior protection from stroke with less

bleeding and without the need for routine monitoring. "

 

At present the drug is only licensed in the UK for the treatment of

orthopaedic patients at risk of clotting after surgery. An application

for permission to use it for the prevention of stroke is pending.